Self-inactivating transposase plasmid for single-vector gene delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transposon and transposase systems for genetic engineering require a two-component approach due to safety concerns, increasing cost and complexity while decreasing efficiency, as they necessitate separate delivery of transposon and transposase.
Innovation Solution
A single-component system utilizing a plasmid that carries a self-inactivating transposase gene and a corresponding transposon, allowing for efficient genetic material delivery by integrating both into a cell using a single vector.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transposon and transposase are delivered separately using a two-component system, then safety concerns are addressed, but cost and complexity increase while efficiency decreases
Solution Approach 1:
The patent combines transposon and transposase into a single plasmid vector, merging two separate delivery components into one integrated system. This reduces complexity while maintaining safety through the self-inactivating transposase design that prevents genomic integration of the transposase gene itself.
Solution Approach 2:
The single plasmid vector performs multiple functions: it delivers both transposon and transposase, contains the self-inactivating safety mechanism, and enables gene delivery all in one component, replacing the need for separate transposon and transposase delivery systems.
2Reliability
If transposon and transposase are delivered separately using a two-component system, then safety concerns are addressed, but delivery efficiency decreases
Solution Approach 1:
By combining transposon and transposase into a single plasmid, the patent eliminates the coordination issues and timing delays associated with separate deliveries, improving delivery efficiency while maintaining safety through the self-inactivating transposase mechanism.
3Reliability
If transposon and transposase are delivered separately using a two-component system, then safety concerns are addressed, but cost increases
Solution Approach 1:
The single plasmid system reduces the quantity of reagents, vectors, and procedural steps required compared to two-component systems, thereby reducing cost while maintaining safety through the self-inactivating transposase design.
4Device complexity
If a single plasmid carries both transposon and transposase, then system complexity is reduced, but safety concerns about transposase integration arise
Solution Approach 1:
The patent converts the potential harm of transposase integration into a benefit by designing a self-inactivating transposase with a defective promoter. The transposase can still function to deliver the transposon, but the defective promoter prevents its own genomic integration, turning a safety risk into a controlled feature.
Solution Approach 2:
The transposase promoter is modified to be self-inactivating, changing the functional parameter of the transposase gene from fully active to conditionally active. This allows the transposase to perform its delivery function while preventing harmful integration into the host genome.
Data Source
AI summary
Some embodiments provided herein relate to gene delivery systems and methods using a single plasmid that carries a self-inactivating transposase gene and a corresponding transposon. Some embodiments include nucleic acids having certain sequences, vector including such nucleic acids, and compositions including the vectors.